Rohan Samson, MD
Cardiovascular Disease · Louisville, KYNPI 1679705263
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,982 of the $93,651 with a category attached, or 74.7%. E.r. Squibb & Sons, L.L.C. accounts for 83.3% of it on its own, with 39 other manufacturers making up the rest. 2025 is the largest year on record at $80,340, more than ten times the $236 reported in 2019. Among cardiovascular disease clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $230.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$78K
- Siemens Medical Solutions USA, Inc.$7K
- Abbott$1K
- Actelion Pharmaceuticals US, Inc.$999
- Pfizer$799
- Novartis$611
- plus $5K from 34 others
Across 4 payments — averaging $108,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$433K
What the payments were for
- Consulting fees$2,8803%
- Speaking & faculty fees$69,98275%
- Travel & lodging$10,73911%
- Food & beverage$9,92311%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$74,529
- Diamondback Coronary$268
- CARDIOMEMS$137
- UPTRAVI$128
- OPSUMIT$128
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$115
- MitraClip$111
- FARXIGA$111
- BVA-100$104
- Legacy$102
How this compares
$93,651 in reported general payments places this provider in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 34 | $806,383 |
| OpsumitMacitentan | 31 | $395,679 |
| VyndamaxTafamidis | 11 | $386,884 |
| VyndaqelTafamidis Meglumine | 12 | $286,085 |
| CamzyosMavacamten | 28 | $234,111 |
| EntrestoSacubitril/Valsartan | 87 | $103,429 |
| EliquisApixaban | 78 | $72,073 |
| JardianceEmpagliflozin | 49 | $53,704 |
| OzempicSemaglutide | 31 | $37,324 |
| FarxigaDapagliflozin Propanediol | 16 | $17,830 |
| XareltoRivaroxaban | 16 | $16,765 |
| Sildenafil Citrate | 30 | $5,509 |
| Bumetanide | 74 | $3,695 |
| Metoprolol Succinate | 312 | $3,450 |
| Potassium Chloride | 107 | $2,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $999 | $1,202,06365 claims |
| PfizerVyndamax, Vyndaqel, Eliquis | $799 | $745,042101 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $78,015 | $234,11128 claims |
| NovartisEntresto | $611 | $103,42987 claims |
| Boehringer IngelheimJardiance | $252 | $53,70449 claims |
| Novo NordiskOzempic | $443 | $37,32431 claims |
| AstraZenecaFarxiga | $415 | $17,83016 claims |
| Johnson & JohnsonXarelto | $86 | $16,76516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Louisville
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- John HarrisLouisville$129K
- Vipul PanchalLouisville$39K
- Steven RaibleLouisville$30K
- Chandhiran RangaswamyLouisville$19K
- Joseph LashLouisville$16K
- Shanker ChandiramaniLouisville$16K
- Pradeep SinghLouisville$15K
- Craig TuckerLouisville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.